Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 5, Pages e1424674
Publisher
Informa UK Limited
Online
2018-01-09
DOI
10.1080/2162402x.2018.1424674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- (2014) Casper Steenholdt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions
- (2014) Alessandra Vultaggio et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- (2013) J. D. Wolchok et al. ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Ipilimumab
- (2011) Fiona Cameron et al. DRUGS
- Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
- (2011) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started